Modified glucagon test allowing simultaneous estimation of insulin secretion and insulin sensitivity: application to obesity, insulin-dependent diabetes mellitus, and noninsulin-dependent diabetes mellitus.
Castillo, M. J.; Scheen, André; Lefebvre, Pierre
1995 • In Journal of Clinical Endocrinology and Metabolism, 80 (2), p. 393-9
Adult; Diabetes Mellitus, Type 1/physiopathology; Diabetes Mellitus, Type 2/physiopathology; Female; Glucagon/diagnostic use; Humans; Insulin/secretion; Insulin Resistance; Male; Obesity/physiopathology
Abstract :
[en] The aim of this study was to describe an adaptation of the glucagon test allowing the simultaneous characterization of insulin secretion and sensitivity. A glucagon test (1 mg/m2) was performed in healthy subjects (n = 11), obese patients (n = 5), insulin-dependent diabetics (n = 9), nonobese noninsulin-dependent diabetics (n = 7), and overweight noninsulin-dependent diabetics (n = 8). Previously, they had been connected to the Biostator, modified for continuous blood collection. Endogenous insulin secretion induced by glucagon was derived from integrated C-peptide concentrations. An index of insulin sensitivity was obtained by dividing the rate of decrease in blood glucose by the total amount of insulin entering the circulation (secreted+infused by the Biostator). The indices of insulin sensitivity obtained in the above groups of subjects were, respectively, 0.064 +/- 0.006, 0.030 +/- 0.006, 0.037 +/- 0.007, 0.021 +/- 0.006, and 0.016 +/- 0.002 mmol/L.U.min (P < 0.001). The estimated insulin secretion values in the 20 min following glucagon injection were, respectively, 0.38 +/- 0.05, 0.65 +/- 0.08, 0.05 +/- 0.01, 0.26 +/- 0.15, and 0.30 +/- 0.07 U (P < 0.001). The insulin sensitivity index obtained from this test correlated with the glucose MCR obtained from a euglycemic glucose clamp (r = 0.816; P < 0.001; n = 12). C-Peptide levels after glucagon administration were also significantly correlated with the estimated endogenous insulin secretion (r = 0.808; P < 0.001; n = 30). This adaptation of the classical glucagon test is an efficient and simple method to simultaneously evaluate insulin secretion and insulin sensitivity.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Castillo, M. J.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Lefebvre, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
English
Title :
Modified glucagon test allowing simultaneous estimation of insulin secretion and insulin sensitivity: application to obesity, insulin-dependent diabetes mellitus, and noninsulin-dependent diabetes mellitus.
Publication date :
1995
Journal title :
Journal of Clinical Endocrinology and Metabolism
ISSN :
0021-972X
eISSN :
1945-7197
Publisher :
Endocrine Society, Chevy Chase, United States - Maryland
Möller DE, Flier JS. 1991 Insulin resistance. Mechanisms, syndromes, and implications. N Engl J Med. 325:938-948.
Reaven GM. 1988 Role of insulin resistance in human disease. Diabetes. 37:1595-1507.
DeFronzo RA, Ferrannini E. 1991 Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 14:173-194.
DeFronzo RA. 1992 Pathogenesis of NIDDM: a balanced overview. Diabetes Care. 15:318-368.
Castillo M, Scheen AJ, Paolisso G, Lefèbvre PJ. 1987 The addition of glipizide to insulin therapy in type II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a residual insulin secretion. Acta Endocrinol (Copenh). 116: 364-372.
DeFronzo RA, Tobin JD, Andres R. 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 237:E214-E223.
Bergman RN, Finegood DT, Ader M. 1985 Assessment of insulin sensitivity in vivo. Endocr Rev. 6:45-86.
Vang YJ, Young JH, Bergman RN. 1987 Modified protocols improve insulin sensitivity estimation using the minimal model. Am J Physiol. 253:E595-E602.
Welch S, Gebhart S, Bergman RN, Phillips L. 1990 Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab. 71: 1508-1518.
Finegood DT, Hramiak IM, Dupré J. 1990 A modified protocol for estimation of insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab. 70:1538-1549.
Osei K, Cottrell DA, Henry ML, Tesi RJ, Ferguson RM, O’Dorisio TM. 1992 Minimal model analysis of insulin sensitivity and glucosemediated glucose disposal in type 1 (insulin-dependent) diabetic pancreas allograft recipients. Diabetologia. 35:676-680.
Coates PA, Ollerton RL, Luzio SD, Ismail IS, Owens DR. 1993 Reduced sampling protocols in estimation of insulin sensitivity and glucose effectiveness using the minimal model in NIDDM. Diabetes. 42:1635-1641.
Quon MJ, Cochran C, Taylor SI, Eastman RC. 1994 Non-insulinmediated glucose disappearance in subjects with NIDDM. Discordance between experimental results and minimal model analysis. Diabetes. 43:890-896.
Faber OK, Binder C. 1977 C-Peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes. 26:605-610.
Castillo MJ, Scheen AJ, Luyckx AS, Lefèbvre PJ. 1983 Blood collection while using a continuous glucose analyzer without insertion of an additional venous catheter. Diabetologia. 25:120-122.
Heding LG. 1975 Radioimmunological determination of human C-peptide in serum. Diabetologia. 11:541-548.
Polonsky KS, Rubenstein AH. 1984 C-Peptide as a measure of the secretion and hepatic extraction of insulin. Diabetes. 33:486-494.
Meistas MT, Zadik Z, Marcolis S, Kowarski AA. 1981 Correlation of urinary excretion of C-peptide with the integrated concentration and secretion rate of insulin. Diabetes. 30:639-643.
Van Cauter E, Mestrez F, Sturis J, Polonsky KS. 1992 Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 41:368-377.
Laposata M. 1992 SI unit conversion guide.Boston: NEJM Books, Massachusetts Medical Society.
Verdonk CA, Rizza RA, Westland RE, Nelson RL, Gerich JE, Service FJ. 1980 Glucose clamping using the Biostator GCIIS. Horm Metab Res. 12:133-135.
Turco C, Brossa G, D’Alberto M, et al. 1981 Kinetic analysis of the response of plasma glucose, insulin and C-peptide to glucagon injection in normal and diabetic subjects. Diabetes. 30:685-692.
Bergman RN, Yang YJ, Hope I, Ader M. 1990 The role of the transcapillary insulin transport in the efficiency of insulin action: studies with glucose clamps and the minimal model. Horm Metab Res. 24(Suppl):49-56.
Saad MF, Anderson RL, Laws A, et al. 1994 A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Diabetes. 43:1114-1121.
Scheen AJ, Paquot N, Castillo MJ, Lefèbvre PJ. 1994 How to measure insulin action in vivo. Diabetes Metab Rev. 10:151-188.
Ferrari P, Alleman Y, Shaw S, Riesen W, Weidmann P. 1991 Reproducibility of insulin sensitivity by the minimal model method. Diabetologia. 34:527-530.
Greenfield MS, Dobeme L, Kraemer F, Tobey T, Reaven G. 1981 Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes. 30:387-392.
Van Itallie TB, Bentley W. 1955 Glucagon induced hyperglycemia as an index of liver function. J Clin Invest. 34:1730-1735.
Hovorka R, Jones RH. 1994 How to measure insulin secretion. Diabetes Metab Rev. 10:91-117.
Leahy JL. 1990 Natural history of B-cell dysfunction in NIDDM. Diabetes Care. 13:992-910.
Porte Jr D. 1991 B-Cells in type II diabetes mellitus. Diabetes. 40: 166-180.
Armer P, Pollare T. 1991 Different aetiologies of type-2 (non-insulindependent) diabetes mellitus in obese and non-obese subjects. Diabetologia. 34:483-487.
Benarji MA, Lebovitz HE. 1989 Insulin-sensitive and insulin-resistant variants in NIDDM. Diabetes. 38:784-792.
Bonadonna RC, Groop LC, Kraemer N, Ferrannini E, DelPrato S, DeFronzo RA. 1990 Obesity and insulin resistance in humans: a dose-response study. Metabolism. 39:452-459.
Castillo MJ, Scheen AJ, Lefèbvre PJ, Luyckx AS. 1985 Insulin-stimulated glucose disposal is not increased in anorexia nervosa. J Clin Endocrinol Metab. 60:311-314.
Davis SN, Monti L, Piatti PM, et al. 1993 Estimates of insulin action in normal, obese and NIDDM man: comparison of insulin and glucose infusion test, CIGMA, minimal model and glucose clamp techniques. Diabetes Res. 23:1-18.
DeFronzo RA, Hendler R, Simonson D. 1982 Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes. 37: 795-701.
Yki-Järvinen H, Koivisto VA. 1986 Natural course of insulin resistance in type I diabetes. N Engl J Med. 315:224-230.
Ward GM, Weber KM, Walters IM, et al. 1991 A modified minimal model analysis of insulin sensitivity and glucose-mediated glucose disposal in insulin-dependent diabetes. Metabolism. 40:4-9.
Scheen AJ, Lefèbvre PJ. 1992 Assessment of insulin resistance in vivo, application to the study of type 2 diabetes. Horm Res. 38:19-27.
Hollenbeck CB, Chen YDI, Reaven GM. 1984 A comparison of the relative effects of obesity and non-insulin-dependent diabetes mellitus on in vivo insulin-stimulated glucose utilization. Diabetes. 33: 622-626.
Scheen AJ, Paolisso G, Castillo M, Jandrain B, Lefèbvre PJ. 1991 Modest but significant influence of obesity in the reduction of insulin-induced glucose disposal in type 2 diabetes mellitus. Int J Obesity. 15(Suppl 1):42A.
Castillo MJ, Scheen AJ, Letiexhe MR, Lefèbvre PJ. 1994 How to measure insulin clearance. Diabetes Metab Rev. 10:119-150.